Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases

Sung Yong Oh, Su-Jin Lee, Jeeyun Lee, Suee Lee, Sung-Hyun Kim, Hyuk-Chan Kwon, Gyeong-Won Lee, Jung Hun Kang, In Gyu Hwang, Joung-Soon Jang, Ho Yeong Lim, Young Suk Park, Won Ki Kang, Hyo-Jin Kim

AIM: To identify the clinical features and outcomes of infrequently reported leptomeningeal carcinomatosis (LMC) of gastric cancer.

METHODS: We analyzed 54 cases of cytologically confirmed gastric LMC at four institutions from 1994 to 2007.

RESULTS: The male-to-female ratio was 32:22, and the patients ranged in age from 28 to 78 years (median, 48.5 years). The majority of patients had advanced disease at initial diagnosis of gastric cancer. The clinicopathologic tumor, node, and metastasis stage of the primary gastric cancer was Ⅳ in 38 patients (70%). The median interval from diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 mo, ranging between 0 and 73.1 mo. Of the initial endoscopic findings for the 45 available patients, 23 (51%) of the patients were Bormann type Ⅲ and 15 (33%) patients were Bormann type Ⅳ. Pathologically, 94% of cases proved to be poorly differentiated adenocarcinomas. Sigmoid ring cell component was also observed in 40% of patients. Headache (85%) and nausea/vomiting (58%) were the most common presenting symptoms of LMC. A gadolinium-enhanced magnetic resonance imaging was conducted in 51 patients. Leptomeningeal enhancement was noted in 45 cases (82%). Intrathecal (IT) chemotherapy was administered to 36 patients—primarily methotrexate alone (61%), but also in combination with hydrocortisone/± Ara-C (39%). The median number of IT treatments was 7 (range, 1-18). Concomitant radiotherapy was administered to 18 patients, and concomitant chemotherapy to seven patients. Seventeen patients (46%) achieved cytological negative conversion. Median overall survival duration from the diagnosis of LMC was 6.7 wk (95% CI: 4.3-9.1 wk). In the univariate analysis of survival duration, hemoglobin, IT chemotherapy, and cytological negative conversion showed superior survival duration ($P = 0.038, P = 0.010, and P = 0.002$, respectively). However, in our multivariate analysis, only cytological negative conversion was predictive of relatively longer survival duration ($3.6, 6.7$ and $14.6$ wk, $P = 0.030, RR: 0.415, 95\% CI: 0.188-0.918$).

CONCLUSION: Although these patients had a fatal clinical course, cytologic negative conversion by IT chemotherapy may improve survival.

© 2009 The WJG Press and Baishideng. All rights reserved.

Key words: Carcinomatosis; Gastric cancer; Intrathecal chemotherapy; Leptomeningeal

Peer reviewers: Gerardo Rosati, MD, Medical Oncology Unit, “S. Carlo” Hospital, Via Potito Petrone, 1, Potenza 85100, Italy; Cuneyt Kayaalp, MD, Professor, Department of General Surgery, Turgut Ozal Medical Center, Inonu University, Malatya 44315, Turkey

Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ. Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases. World J Gastroenterol 2009;
INTRODUCTION

Leptomeningeal carcinomatosis (LMC) is defined as malignant infiltration of the pia mater and the arachnoid membrane. LMC is one of the most serious complications that can occur in cancer patients\(^1\). According to the results of a large autopsy study, the incidence of LMC was 5%-8% in cancer patients\(^2\). As a significant proportion of these patients have asymptomatic microscopic disease, the clinical diagnosis of LMC has been established in 2%-4% of patients during the course of their malignancy\(^3\). LMC is frequently detected in patients with leukemia, breast cancer, lymphoma, and lung cancer\(^4\). Among solid tumors, LMC is observed more frequently in cases of disseminated and progressive disease. Although a subset of patients, particularly those with lymphoma or breast cancer, may survive for more than 12 mo with a reasonable quality of life, leptomeningeal metastasis from solid tumors is associated with a poor overall prognosis. The treatment of LMC is palliative and unsatisfactory. No evidence demonstrating the superiority of intrathecal (IT) treatment compared to best palliative care is currently available from clinical trials.

Furthermore, the development of LMC from a gastric cancer is a very rare occurrence. Some articles have reported that the incidence of LMC in patients with gastric cancer was responsible for 0.16% of all cases of gastric cancer\(^5\). Due to its rarity, the clinical features and prognostic factors of LMC as a metastasis from gastric carcinoma have yet to be clearly characterized. The benefits of IT chemotherapy are also currently a matter of some contention.

Gastric cancer is the most common malignancy in Korea\(^6\). Because of the high prevalence of gastric cancer in Korea, we took the opportunity to study gastric cancer patients with LMC. The principal objective of this study was to review our experience with LMC associated with gastric cancer, and to evaluate its clinical features and the efficacy of a variety of treatment modalities in terms of neurological status and overall survival (OS).

MATERIALS AND METHODS

Patients

From 1995 to 2007, 22,154 patients were diagnosed with gastric cancer at four independent institutions. Among them, 54 patients who were diagnosed with leptomeningeal seeding metastasis of gastric cancer were analyzed. Although it is not representative of the cohort of patients, the prevalence of LMC was 0.24%.

Eligibility for this study included: (1) patients with histologically confirmed adenocarcinoma of the stomach; (2) cytologically confirmed malignancy on cerebrospinal fluid (CSF) analysis, patients with suspected LMC by magnetic resonance imaging (MRI) and negative cytology were excluded; (3) no history of any other malignancies.

We retrospectively analyzed the patients’ medical records including the patients’ characteristics, clinical symptoms, laboratory and radiologic findings, treatment modality and outcomes, final follow-up, and survival duration.

Statistical analysis

Comparisons of categorical variables among groups were conducted using the chi-square test and Fisher's exact test. OS was calculated from the cytological confirmation of LMC and plotted via the Kaplan-Meier method. Comparison of survival according to prognostic factors was evaluated via a log-rank test, and forward stepwise Cox proportional hazard models were employed to evaluate the joint effect of predictive variables. \(P < 0.05\) was considered significant. Analysis of the data was conducted using SPSS for Windows V. 15.0 (SPSS Inc., Chicago, IL, USA) statistical software.

RESULTS

Patients’ characteristics

We analyzed 54 cases of cytologically confirmed gastric LMC at four institutions from 1994 to 2007. The clinical characteristics of these patients are summarized in Table 1. The male-to-female ratio was 32:22, and patients ranged in age from 28 to 78 years (median, 48.5 years). The majority of patients had advanced disease at initial diagnosis of gastric cancer. The clinical or pathologic tumor, node and metastasis stage of the primary gastric cancer was IV in 47 patients (87%). Stage I – III patients received curative operation. Among the stage IV patients, 13 patients had T4N1-2 or N3 (No. of nodes > 15) by pathologic features through curative operation. M1 node positive patients were counted as palliative surgery. Of the initial endoscopic findings in the available 45 patients, Bormann type III and IV were reported for 23 (51%) and 15 (33%) patients, respectively. Pathologically, 94% of cases proved to be poorly differentiated adenocarcinomas. Signet ring cell component was also observed in 40% of patients.

LMC patterns

The median interval from diagnosis of the primary gastric cancer to the diagnosis of LMC was 6.3 mo, ranging from 0 to 73.1 mo. Five patients presented with initial LMC. The majority of patients (59.3%) initially presented with metastatic gastric cancer without LMC, and then progressed to LMC. One-third of the patients presented with curable disease at the initial diagnosis of gastric cancer (Table 2).

Clinical symptoms

The most frequently observed presenting symptoms of LMC were nonspecific symptoms such as headache (85%) and nausea/vomiting (58%). In addition, various neurological clinical signs and symptoms were noted.
including altered mental status, seizure, motor weakness, sensory change, diplopia, hearing loss, and facial palsy (Table 3).

CSF analysis and image findings
Lumbar puncture and analysis of CSF is a crucial laboratory test in the diagnosis of LMC. All the patients presented with malignant cells on cytological analysis via the inclusion criteria. An elevated opening pressure on lumbar puncture was noted in 58% of the subjects. The mean CSF pressure in the patients was 222.1 mm CSF. 78.8% and 53.8% of patients had elevated white blood cells and protein in CSF, respectively (Table 4).

Brain computed tomography was assessed in eight patients and leptomeningeal enhancement was observed only in one patient. A gadolinium-enhanced MRI was conducted in 51 patients. Leptomeningeal enhancement was noted in 45 cases (82%).

Treatment modalities and outcomes
IT chemotherapy was administered to 36 patients, principally with methotrexate (MTx) alone (61%) or in combination with hydrocortisone/± Ara-C (41%). The median number of IT treatments was 7 (range, 1-18).

Seventeen patients (46%) achieved cytological negative conversion (Table 5).

Thirteen patients were treated with whole brain irradiation coupled with IT chemotherapy. Six patients received radiation treatment alone.

Additional systemic chemotherapy was given to 10 patients. Three patients were treated with the orally available 5-fluorouracil (5-FU) drugs - capecitabine, S-1, and tegafur-uracil. Irinotecan/leucovorin/5-FU, 5-FU/cisplatin, and paclitaxel/cisplatin were administered to four, two and one patients, respectively. Seven patients were treated with chemotherapy plus IT chemotherapy. Three patients received chemotherapy alone. The median number of cycles administered was 2 (range, 1-6).

Among the treated patients, only one exhibited a detectable response to treatment.

Survival and prognostic factors
Median OS duration from diagnosis of LMC was 6.7 wk (95% CI: 4.3-9.1 wk) (Figure 1). In the univariate analysis of survival duration, hemoglobin, IT chemotherapy, and cytologic negative conversion showed superior
survival duration \( (P = 0.038, P = 0.010, \) and \( P = 0.002, \) respectively). However, in the multivariate analysis, only cytologic negative conversion was predictive of relatively longer survival duration \( (3.6, 6.7 \) and \( 14.6 \) wk, \( P = 0.030, \) RR: \( 0.415, 95\% \) CI: \( 0.188-0.918 \)) (Table 6, Figure 2).

**DISCUSSION**

Adenocarcinoma is the predominant histological type in LMC of solid tumors. Among patients diagnosed with LMC, the most frequently encountered solid tumors are breast (12%-34%), lung (14%-29%), and melanoma (17%-25%). Unlike Western reports, gastric cancer is the principal etiology of LMC in solid tumors in Korea. CNS metastasis is a very rare complication of gastric cancer, and occurs in 0.16%-0.69% of gastric cancer patients in general, including Korean reports. Although all the included patients demonstrated CSF cytologically confirmed malignancy, the prevalence of LMC in this study was 0.24% in all gastric cancer patients.

Consistent with other studies, the majority of patients had Bormann type III or IV advanced gastric cancer of poorly differentiated or signet-ring cell histopathology, which increased the tendency for distant metastasis and poor prognosis. Similar to the results of a previous study, LMC patients presented with an advanced stage and Bormann type III or IV advanced gastric cancer of poorly differentiated or signet-ring cell histopathology.

LMC is an ultimately fatal disease. A minority of patients, usually those with breast cancer or lymphoid malignancies, may achieve disease-free survival of a year or more, however, the median OS for patients with LMC is only 4-6 wk if untreated and 2-4 mo with therapy. In our study, the median survival duration was just 6.7 wk (95% CI: 4.3-9.1 wk).

**Table 5** Treatment with intrathecal chemotherapy (\( n = 36 \))

| Regimen                          | \( n \) (%) |
|---------------------------------|-------------|
| MTx                             | 22 (61.1)   |
| MTx + steroid                   | 4 (11.1)    |
| MTx + Ara-C + steroid           | 10 (27.8)   |
| Concurrent/sequential           |             |
| + alone                         | 16 (44.4)   |
| + radiotherapy                  | 13 (36.1)   |
| + chemotherapy                  | 2 (5.6)     |
| + chemoradiotherapy             | 5 (13.9)    |

**Table 6** Survival duration and prognostic factors

| Factors                      | Median OS (mo) | Univariate | Multivariate |
|------------------------------|----------------|------------|-------------|
| Gender                       |                |            |             |
| Male                         | 7.1            | 0.491      | -           |
| Female                       | 6.7            |            |             |
| Age (yr)                     |                |            |             |
| > 60                         | 12.4           | 0.214      | -           |
| ≤ 60                         | 6.4            |            |             |
| PS (LMC)                     |                |            |             |
| 0, 1                         | 11.7           | 0.975      | -           |
| ≥ 2                          | 6.4            |            |             |
| Hb (LMC)                     |                |            |             |
| > 11                         | 5.7            |            |             |
| ≤ 11                         | 12.4           | 0.038      | NS          |
| MRI enhance                  |                |            |             |
| Negative                     | 5.7            | 0.316      | -           |
| Positive                     | 7.1            |            |             |
| CSF pressure                 |                |            |             |
| > 120                        | 6.4            | 0.163      | NS          |
| ≤ 120                        | 8.1            |            |             |
| CSF protein                  |                |            |             |
| > 40                         | 6.0            | 0.539      | -           |
| ≤ 40                         | 11.7           |            |             |
| IT chemotherapy              |                |            |             |
| No                           | 3.6            | 0.010      | NS          |
| Yes                          | 11.7           |            |             |
| Radiotherapy                 |                |            |             |
| No                           | 4.6            | 0.516      | -           |
| Yes                          | 6.9            |            |             |
| Cytologic response           |                |            |             |
| No                           | 5.1            | 0.002      | 0.030       |
| Yes                          | 14.6           |            | (HR: 0.415, 95\% CI: 0.188-0.918) |

OS: Overall survival; PS (LMC): Performance status scale by Eastern Cooperative Oncology Group at leptomeningeal carcinomatosis; Hb (LMC): Hemoglobin at leptomeningeal carcinomatosis; MRI: Magnetic resonance imaging; CSF: Cerebrospinal fluid; IT: Intrathecal; HR: Hazard ratio; CI: Confidence interval.

**Figure 1** Median overall survival (OS) duration from diagnosis of leptomeningeal carcinomatosis. Median OS was 6.7 wk (95% CI: 4.3-9.1 wk).

**Figure 2** Cytologically negative conversion proved predictive of relatively longer survival duration \( (P = 0.030, \) RR: \( 0.415, 95\% \) CI: \( 0.188-0.918 \)).
6.7 wk. Although LMC patients tend to have a poor performance status, approximately two-thirds of patients who receive IT chemotherapy and 47.2% of patients who responded to therapy achieved longer survival duration. The independent prognostic factor for survival was cytologic negative conversion by IT chemotherapy. Although the small sample size and inherent selection bias of the retrospective design of this study makes any conclusions regarding the outcomes of treatment somewhat difficult, the findings of our study indicate that cytologic negative conversion by IT chemotherapy may improve survival by arresting neurologic progression in selected patients.

MTX remains the most frequently utilized drug for IT administration, despite its limited success and serious complications[16,17]. Combination IT chemotherapy with MTX, arabinoside and hydrocortisone has been reported to be more effective than MTX alone in solid tumor LMC[18]. However, approximately 10% of gastric cancer patients were enrolled in this study, and the efficacy of arabinoside against gastric cancer is questionable.

Craniospinal irradiation may be a one-treatment modality. However, the additional or sequential role of radiation has been controversial[19]. In our study, additional effects of radiotherapy were not observed. As response to radiation is associated with the sensitivity or resistance of primary tumors and malignant cells circulating in the CSF space, radiation is occasionally not feasible for palliative treatment.

Systemic chemotherapy was also administered to a limited number of patients who had better performance status[6,15,18]. In our study, patients who were treated with systemic chemotherapy showed the best median OS duration (21.6 wk, 95% CI: 3.2-40 wk). However, all the treatments were administered sequentially after IT chemotherapy and the patients responded to treatment.

REFERENCES

1. Pentheroudakis G, Pavlidis N. Management of leptomeningeal malignancy. Expert Opin Pharmacother 2005; 6: 1115-1125
2. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Res 1999; 25: 103-119
3. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49: 759-772
4. Kim M. Intracranial involvement by metastatic advanced gastric carcinoma. J Neurooncol 1999; 43: 59-62
5. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, Seo SW, Kim KY, Lee SY, Kang IS, Hwang IK, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM, Yoo KY. National cancer incidence for the year 2002 in Korea. Cancer Res Treat 2007; 39: 139-149
6. Bruno MK, Raizer J. Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). Cancer Treat Rev 2005; 125: 31-52
7. Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH. Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol 2004; 66: 167-174
8. Kasakura Y, Fuji M, Noguchi Y, Suzuki T, Takahashi T. Clinicopathological study of brain metastasis in gastric cancer patients. Surg Today 2000; 30: 485-490
9. York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol 1999; 6: 771-776
10. Noguchi Y. Blood vessel invasion in gastric carcinoma. Surgery 1990; 107: 140-148
11. Adachi Y, Mori M, Maehara Y, Sugimachi K. Poorly differentiated medullary carcinoma of the stomach. Cancer 1992; 70: 1462-1466
12. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005; 23: 145-154
13. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38: 245-252
14. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994; 51: 457-461
15. Chowdhary S, Chamberlain M. Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Canc Neto 2005; 3: 693-703
16. Aiello-Laws L, Rutledge DN. Management of adult patients receiving intrathecal chemotherapy for the treatment of leptomeningeal metastasis. Clin J Oncol Nurs 2008; 12: 429-435
17. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973; 289: 770-773
18. Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, Kim TV, Heo DS, Bang YJ, Kim NK. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 2003; 33: 608-612
19. Mehta M, Bradley K. Radiation therapy for leptomeningeal cancer. Cancer Treat Res 2005; 125: 147-158
20. Taillibert S, Hildebrand J. Treatment of central nervous system metastases: parenchymal, epidural, and leptomeningeal. Curr Opin Oncol 2006; 18: 637-643

S-Editor Tian L  L-Editor Webster JR  E-Editor Zheng XM